Sulfamethoxazole Standard (98%)

A phenomenon of supramolecular solvents formation in aqueous solutions containing primary amine and monoterpenoid compound is presented for the first time. A novel supramolecular solvent-based liquid phase microextraction was developed. In an aqueous phase primary amine formed isotropic solution due to formation of amphiphile supramolecular assembly. The phase separation was achieved by a coacervation process. The monoterpenoid phenol (thymol) acted as a coacervation agent and induced spontaneous in situ formation of tiny supramolecular solvent droplets. The applicability of the proposed microextraction procedure was demonstrated for the separation of sulfonamides from biological fluids (human plasma and serum). An obtained composition of supramolecular solvent (1-decylamine, thymol, water) promoted satisfactory extraction of polar analytes from aqueous phase. The calibration graphs were linear over the concentration ranges of 0.06-50 mg L-1 for sulfamethoxazole, sulfamethazine and sulfapyridine. The limit of detection calculated from the blank tests based on 3s was 0.02 mg L-1 for all analytes. The total analysis time was 15 min.

A Polymerase Chain Reaction-based diagnosis ofPneumocystisPneumonia (PCP) and the need for anti-Pneumocystisprophylaxis in Hodgkin lymphoma patients receiving chemotherapy requires further investigation. This retrospective, single-center, study evaluated 506 consecutive adult patients diagnosed with Hodgkin lymphoma receiving chemotherapy between January 2006 and August 2018. The cumulative incidence of PCP 1 year after start of chemotherapy was 6.2% (95% CI 3.8-8.5%). Mortality 30 days from PCP diagnosis was 8% (n = 2) with one death attributable to PCP. Bleomycin-containing combination chemotherapy regimen was not significantly associated with a higher risk for PCP when compared to other regimens (HR = 1.59, 95% CI 0.55-4.62p = 0.40). Anti-Pneumocystisprophylaxis was not significantly associated with a decreased incidence of PCP (HR = 0.51, 95% CI 0.15-1.71,p = 0.28). As the overall incidence is above the commonly accepted 3.5% threshold, clinicians should consider the potential value of prophylaxis. The utility of universal vs. targeted anti-Pneumocystisprophylaxis requires prospective, randomized investigation.